X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - X4 Pharmaceuticals reported a quarterly loss of $0.69 per share, better than the Zacks Consensus Estimate of a loss of $0.79, and a significant improvement from a loss of $5.41 per share a year ago, resulting in an earnings surprise of +12.66% [1] - The company generated revenues of $1.77 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 7.2%, but showing growth from $0.56 million in the same quarter last year [2] - X4 Pharmaceuticals shares have declined approximately 82% year-to-date, contrasting with the S&P 500's gain of 15.1% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend of estimate revisions for X4 Pharmaceuticals was favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy), indicating expected outperformance in the near future [6] - Current consensus EPS estimate for the next quarter is -$0.44 on revenues of $2.1 million, and for the current fiscal year, it is -$3.40 on revenues of $34.81 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which X4 Pharmaceuticals belongs, is currently ranked in the top 40% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Alvotech, another company in the same industry, is expected to report quarterly earnings of $0.05 per share, reflecting a year-over-year decline of 73.7%, with revenues projected at $128.22 million, up 24.5% from the previous year [9]